How Radiomics Predicts TACE Outcomes in Liver Metastases

Introduction

Selecting appropriate patients for irinotecan-TACE remains a significant challenge for oncologists worldwide. Recently, the CIREL trial demonstrated that Radiomics for TACE outcomes can provide critical prognostic information. This innovative approach utilizes machine learning to analyze medical imaging at a level invisible to the human eye. Consequently, clinicians can now identify individuals who are most likely to benefit from this locoregional therapy. Furthermore, this method allows for a more personalized treatment strategy in managing colorectal liver metastases.

The Role of Radiomics for TACE Outcomes in Patient Selection

Researchers analyzed data from 76 patients with 176 lesions to develop their predictive models. Specifically, the study tested intensity-based features, general radiomics, and lesion volume. On external validation, the baseline intensity algorithm emerged as the most accurate survival-prediction model. Moreover, delta radiomics proved highly effective at identifying lesion-level responses during follow-up. Therefore, these tools help clinicians distinguish between high-risk and low-risk patient groups. In fact, low-risk patients showed a median survival of nearly 700 days compared to 453 days for those at higher risk.

Enhancing Clinical Decision Making

Integrating these imaging features with laboratory data further enhanced the assessment of lesion-level response. However, this integration did not significantly improve the prediction of overall survival. Consequently, the researchers recommend using specific imaging markers for different clinical goals. While baseline intensity predicts long-term survival, delta radiomics focuses on immediate treatment efficacy. By adopting these models, medical teams can avoid unnecessary interventions in non-responding patients. Ultimately, this leads to improved survival and better resource allocation in oncology centers.

Frequently Asked Questions

Q1: Which imaging marker best predicts overall survival for patients receiving irinotecan-TACE?

The baseline intensity algorithm proved to be the most effective predictor of survival. It significantly outperformed both general radiomics and simple lesion volume assessments.

Q2: How does delta radiomics differ from baseline assessments in this study?

Baseline assessments focus on information from images taken before treatment starts. In contrast, delta radiomics analyzes changes between baseline and follow-up images to determine how a specific lesion responds to therapy.

References

1. Bodalal Z et al. Radiomics-based outcome prediction for irinotecan-TACE in colorectal liver metastases: advanced analysis from the prospective CIREL trial. Eur Radiol. 2026 Apr 29. doi: 10.1007/s00330-026-12573-w. PMID: 42053592.
2. Arnold D et al. CIREL study finds comparable overall survival between indication for irinotecan-TACE in colorectal liver metastases. ESMO Open. 2025;10(3):104292.
3. Viglino M et al. Radiomics in Predicting Therapeutic Response in Colorectal Liver Metastases. MDPI. 2022;14(20):5034.

“